Tiemann Investment Advisors LLC Has $1.42 Million Position in Eli Lilly and Company (NYSE:LLY)

Tiemann Investment Advisors LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 1.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,837 shares of the company’s stock after selling 30 shares during the period. Tiemann Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $1,418,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of LLY. Principal Financial Group Inc. lifted its holdings in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after acquiring an additional 60,306 shares during the period. Assetmark Inc. raised its position in Eli Lilly and Company by 7.3% during the third quarter. Assetmark Inc. now owns 49,713 shares of the company’s stock valued at $44,043,000 after purchasing an additional 3,397 shares in the last quarter. Field & Main Bank lifted its stake in Eli Lilly and Company by 0.3% during the third quarter. Field & Main Bank now owns 8,172 shares of the company’s stock worth $7,240,000 after purchasing an additional 27 shares during the last quarter. First Personal Financial Services boosted its holdings in shares of Eli Lilly and Company by 24.9% in the 3rd quarter. First Personal Financial Services now owns 301 shares of the company’s stock valued at $267,000 after purchasing an additional 60 shares in the last quarter. Finally, Sheets Smith Wealth Management boosted its holdings in shares of Eli Lilly and Company by 48.6% in the 3rd quarter. Sheets Smith Wealth Management now owns 13,065 shares of the company’s stock valued at $11,574,000 after purchasing an additional 4,271 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $868.59 on Monday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a one year low of $711.40 and a one year high of $972.53. The business’s 50 day simple moving average is $826.63 and its 200 day simple moving average is $847.24. The stock has a market capitalization of $823.57 billion, a PE ratio of 74.17, a PEG ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its Board of Directors has approved a stock repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research note on Friday, January 17th. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Truist Financial lifted their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, Citigroup dropped their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,007.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.